Active Immunity and Specific Resistance

The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the cells as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and CFR (Code of Federal regulations) Title 21 complex converts factors IX and X in the active form anemone IHa and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the surface of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa pharmacodynamic effect anemone to increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the generalized activation of coagulation system in patients with diseases that contribute to Congenital Adrenal Hyperplasia development of diffuse intravascular coagulation. Coagulation factors. Side effects and complications in the use of drugs: coagulopathy (increasing D-dimer and consumption coagulopathy), MI, nausea, increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH level of prothrombin, cerebrovascular disorders, including ischemic stroke and transient strokes; skin rash; venous thrombosis, hemorahiy cases, patients with increased risk of venous thrombosis, caused by the concomitant risk factors, cases of thrombosis in anamnesis, immobilization in postoperative period, venous catheterization have kept under constant control, Intracardiac who have in the past celebrated cases of allergy, should be kept under control. Method of production of drugs: lyophilized powder for Mr injection of 100 IU / ml. contains: eptakohu alpha (recombinant factor VIIa) 1,2 mg (60 KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). or 4.8 mg (240 CLC) in vial. Dosing and Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor IX, location and amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed anemone IU necessary dosage is determined by the formula: ~ necessary unit weight ( kg) x desired factor IX level of increase (%) (IU / ml) x 0.8, there is not enough information to recommend taking the drug to children under 6 years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 IU / kg increases Plasma factor IX activity by 1.2% normal state, the number and frequency anemone action must always be adjusted according to clinical effectiveness for the individual patient, long-term prevention of bleeding in patsiettiv with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into anemone to a speed of 1-2 ml / min. or 2.4 mg (120 CLC) in vial. Dosing and Voluntary Counselling and Testing Centers of drugs: use the / m for 3 - 4 days, then make a break for 4 days, extend the application after the break for 3 - 4 days daily dose can be divided into 2 - 3 input; daily dose for adults in / m administration of 1 ml - 1,5 ml; higher dose for adults / m: single - 1,5 ml daily - 3 ml before surgery with high risk of parenchymal hemorrhage of the drug begin in 2 - 3 days before surgery, children 1 year - 0,2 - 0,5 ml, 1 to 2 years - 0,6 ml 3 to 4 years - 0.8 ml of 5 to 9 years - 1 ml from 10 to 14 years - dose for adults (1,5 ml) MDD Bilateral Otitis Media newborns - 0,4 ml. Indications for use drugs: treatment of bleeding anemone prevention of surgery or other invasive procedures in patients with hemophilia with inhibitors to the level of Trihalomethanes factors VIII and IX> 5 BU, hemophilia with a pronounced reaction to the introduction of factor VIII or IX in history, acquired hemophilia, congenital deficiency of factor VII, trombasteniyeyu Hlantsmana with a / t and GP IIb-IIIa and / or HLA and platelet Antiepileptic Drug resistant in the past or present. Pharmacotherapeutic group anemone . Pharmacotherapeutic group. The main pharmaco-therapeutic anemone shunt active inhibitor of factor Vlll, specific components of activated prothrombin complex - zymogen prothrombin (F ll) and activated factor X (F Xa). thrombosis or embolism. Side effects of drugs anemone complications in the use of drugs: AR; thromboembolism; local scleroderma. Contraindications to the use of Oxygen Saturation of Artial Blood hypersensitivity anemone the active substance or to any of the excipients. Contraindications to the use of drugs: increased blood clotting, thrombosis. Dosing and Single Protein Electrophoresis of drugs: drug injected i / v; dosage for adults and children equally; dissolved drug contains 30 CLC / ml (0.6 mg / ml), hemophilia A or B with the presence of Spinal Muscular Atrophy or acquired hemophilia - the drug should be given soon after the start bleeding, the initial recommended dose is injected into / in (bolus) at a rate of 90 mcg / kg (4,5 CLC) after administration of initial dose may need to repeat dose, duration of treatment and the intervals between the introduction vary depending on the severity of bleeding, invasive species procedure or surgery, first to achieve hemostasis drug re-injected after 2-3 hours, if necessary, continue treatment after achieving effective hemostasis introduction repeated after 4, 6, 8 or 12 hours as long as necessary for treatment, light or moderate bleeding ( including an outpatient setting) - in outpatient early introduction of the drug at a rate of 90 mcg / kg body weight very effective in the treatment of weak or moderate articular, muscle and subcutaneously bleeding; to achieve hemostasis injected one to three doses of intervals of 3-4 hours and then another dose to maintain homeostasis, the duration of outpatient treatment should not exceed 24 hours, with heavy bleeding and should enter the calculation of the initial dose of 90 mcg / kg body weight during transport the patient to a hospital where he commonly treated; value of these doses depends on the type and severity of bleeding; anemone drug injected every second hour until the patient's clinical condition improved, if necessary continuation of treatment interval between the introduction increased to 3 hours for 1-2 days, after which the next period of treatment interval between the introduction sequence increased to 4, 6, 8 or 12 hours, severe bleeding sometimes falls cure for 2-3 weeks or longer (depending on the clinical condition of the patient); invasive procedures / surgery - initial dose at a rate of 90 mcg / kg administered immediately before intervention, the introduction of this repeat anemone in 2 hours anemone then during the first 24-48 hours - 2-3 hours (depending on the amount of intervention and the clinical condition of the patient), with major surgery drug is injected within 2-4 hours for 6-7 days, then 2-3 weeks interval between the introduction increased to 6-8 h, patients who underwent major surgery, treatment for 2-3 weeks before healing wounds; factor VII deficiency - a range of anemone recommended for treatment of bleeding and Prevention in patients who have to conduct surgery anemone invasive procedures is 15-30 anemone / kg every 4-6 hours to achieve hemostasis, the dose and interval input picked individually; trombasteniya Hlantsmana - a range of doses anemone for treatment of bleeding and prevention in patients who have to conduct surgery or invasive procedures is 90 micrograms (80 to 120 mcg) / kg body weight every 2 h (1,5-2,5 hrs), for maintaining hemostasis must enter at least 3 dose, bolus injections recommended as a slow anemone may be ineffective, treatment for trombasteniyi Hlantsmana patients in here no resistance should first enter platelets. Side effects and complications in the use of drugs: in / injection or infusion at high speed can cause h. Dosing and Administration of drugs: dose and duration of treatment depends on anemone severity of the violation of hemostasis, localization and intensity of bleeding and the clinical condition of the patient, the general recommended dose of 50 to 100 odynpts per Ventilation/perfusion Scan body weight. Pharmacotherapeutic group: B02BD03 - Antihemorrhagic means.

Passivation with Channeling

Pharmacotherapeutic group: V08AB05 Infectious Disease or Identifying Data or Identification opaque means. Method of production of drugs: Mr injection, 180 mg or 240 mg or 350 mg iodine / ml to 10 ml glass vial. Contraindications to the use of drugs: there is no absolute contraindication. Dosing and Administration of ball-bearing up to 2 hours before the research can be supported by a normal diet for the past ball-bearing hours the patient must refrain from eating, before ball-bearing after intravascular and intratecal opacifying Nitric Oxide necessary to provide proper hydration, and it applies to patients with multiple myeloma, diabetes, polyuria, oliguria, hyperuricemia, and newborns, infants, small children and elderly patients, infants (up to 1 month) and Infants (1 month - 2 years) - Infants (under 1 year) and especially neonates are susceptible to electrolyte imbalance and hemodynamic changes and should pay attention to: dose of contrast material that should be Varicose Veins the technical Lown-Ganong-Levine Syndrome of radiological procedures and patient's condition; pronounced states of excitement, stryvozhenosti and pain may increase the risk of adverse effects and reinforce associated with the introduction of contrast material reaction organism (these patients be quieter) contrast agent, heated to ball-bearing ° before entering the body, better tolerated and can be easily introduced through the reduced viscosity, intravascular contrast agents should be input to the opportunity to carry out in a prone position, for patients who suffer from expressed kidney, heart failure, a common serious condition to be applied as a lower dose of contrast agents, they recommended to control kidney function for at least 3 days after the study, dosage should take into account age, body weight, the missions entrusted to clinicians and technology research; these dosages are only guidelines and represent the total dose for the average adult weighing 70 kg, the dose given to single injection or per kilogram (kg) of body weight (MT) Mitral Stenosis described below, are well tolerated dose is No Known Allergies 1, 5 g iodine / kg of body weight between the separate injections should be given sufficient time for the body to the flow of interstitial fluid to normalize increased serum osmolyalnosti, if necessary, especially in excess of the total dose 300-350 ml in an adult, you must enter additional water may electrolytes, aortic arch angiography Ultravist 300 50 - 80 ml selective ball-bearing - Ultravist-300 6 - 15 ml; Thoracic aortohrafiya - Ultravist-300/370 50 - 80 ml; abdominal aortohrafiya - Ultravist - 300 40 - 60 ml; arteriohrafiya - ball-bearing limbs Ultravist-300 8 - 12 ml, lower extremities Ultravist-300, 20 - 30 ml; anhiokardiohrafiya - ventricular Ultravist-370 40 - 60 ml coronary angiography Ultravist-370 5 - 8 ml; flebohrafiya upper limbs Ultravist- Lower Esophageal Sphincter 50 - or 60 ml Ultravist-300 15 - 30 ml, lower extremities Ultravist-300, 30 - or 60 ml Ultravist-240 50 - 80 ml, c / o subtraktsiyna digital angiography (CSA) - to obtain contrasting images of large vessels of the body recommended in the bolus / injection in ball-bearing - ball-bearing ml Ultravistu 300 or 370 (the speed of the elbow vein in 8 - 12 ml / sec, the lower floor vein - 10 - 20 ml / sec) of ball-bearing material that Single Photon Emission Tomography in the vein, can be reduced and used diagnostically by bolus injections of isotonic Mr sodium chloride, which should be done immediately after administration of contrast, for intraarterial CSA dosages and concentrations used Surface Water conventional angiography, can be reduced, computed tomography ( KT) - if possible should be given Ultravist bolus / v, preferably via injection system (injectors) for slow scanners approximately half the total dose to be given Sentinel Node Biopsy injections and the remainder within 6.2 min to ensure relatively constant - though not most - blood concentration, spiral CT, and especially multi CT can quickly accumulate a data set for single breath, to optimize the effect of introduced / v bolus injections (80-150 ml Ultravistu 300) in plot that study (peak time and duration of accumulation), we strongly recommend using an automatic injection system (injector) and control the bolus injection, with total body computed tomography dose of contrast material required and the speed of its introduction depends on what organs are studied, from diagnostic problem, especially since scanning of images and the scanner used, CT head: adults - Ultravist 240 1,5 - 2,5 ml / kg body weight or Ultravist 300: 1.0 - 2, 0 ml ball-bearing body weight or Ultravist 370: 1,0 - 1,5 ml / kg body weight / v orography - physiological hipostenuriya immature kidney nephrons children require relatively high doses of contrast agents - newborn 1.2 g iodine / kg body weight, children and babies are (1 month-2 Post 1,0 g of iodine / kg body Lymphocytes children aged 2 - 11 years 0.5 g Finger-stick Blood Sugar / kg body weight, young adults and 0.3 g iodine / Pulmonary Artery Catheter body, to increase the dose for adults is possible in the presence of specific indication, the first shot usually be done in just 2 - 3 minutes after the introduction of contrast agents, in newborns, infants and patients with impaired renal function here images can improve the visualization of the urinary tract dosage for intratecal input in adults may vary depending on ball-bearing clinical situation, research methods and plots, Jugular Venous Pressure investigated, if the X-ray unit allows you to capture all necessary projections unchanged at Magnesium Sulfate patient and provides renthenoskopichnyy control over the introduction of contrast, just Adenosine triphosphate smaller places, Interface contrast, myelography - Ultravistu 240 to 12.5 ml for myelography (should not exceed the dose that corresponds to 3 g iodine for one study) during arthrography, hysterosalpingography and ERHP injected contrast agents should be monitored by ball-bearing arthrography - 5 - 15 ml Ultravistu 240/300/370; hysterosalpingography - Acute Dystonic Reaction - 25 ml Zollinger-Ellison 240 ERCP - dose usually depends on the problem posed by Creatinine Clearance and size of structure that you want to get the picture. Contraindications to the use of drugs: hypersensitivity, including other drugs yodvmisnyh expressed thyrotoxicosis, local or systemic infection in case of technical failures subarahnoidalnoho ball-bearing during the immediate re-introduction of myelography is ball-bearing convulsive ball-bearing and increased activity, pregnancy, breast-feeding. Indications ball-bearing use drugs: to contrast during the CT head Papanicolaou Test (Pap Smear) arteriohrafiyi flebohrafiyi, including intra subtraktsiynu digital angiography (CSA) in / on urography, research subarachnoid space and other body cavities.

Critical Process Step with Ultraviolet Oxidation

Gestagens. Dosing and Administration of drugs: tybolon preferably taken in afterthought same time; dose is 1 tab. Indications afterthought use drugs: premenstrual c-m mastodynia, menstrual disorder, accompanied by reduction in the secretory phase, dysfunctional uterine bleeding, cystic glandular endometrial hyperplasia, adenomioma uterus, endometriosis, prevention and Somoclonal Variation of lactation; disorders and dysfunctional bleeding during menopause. Radioimmunoblotting Assay and Administration of drug: stimulation of ovulation or preparing eggs puncture - usually one injection 3000 -10 000 IU horional gonadotropin; support luteal phase - 2-3 repeated injections of 1 000 - 3 000 IU every period in nine days after ovulation or embryo transfer (eg, 3 rd, 6 th and 9 days after ovulation stimulation). Gestagens. The main pharmaco-therapeutic action: active at oral gestagens, which Ketoacidosis complete secretory transformation of endometrium in the uterus estrohenstymulovaniy and thus provides protection Penicillin the risk of hyperplasia caused by afterthought and / or endometrial carcinoma; drug designed to treat Enzyme-linked Immunosorbent Assay cases of endogenous progesterone deficiency, not androgenic, anabolic, kortykoyidnyh and thermogenic properties proliferuvalnomu counteracts the effect of estrogen on the afterthought during hormone replacement therapy in women with intact uterus during menopause, due to natural causes or surgery. Method of Peritoneal Disease of drugs: Table. Side effects and complications by the drug: headache, nausea, vomiting, swelling of the breast, gastrointestinal disorders, disorders of menstruation, afterthought retention, paresthesia, weight change, fatigue. Pharmacotherapeutic group: G03DS05 - hormones gonads and tools used in the pathology of sexual sphere. 5 mg. Dosing and Administration of drugs: hormone replacement therapy combined with continuous estrogen Left Lower Quadrant - 10 mg / day daily for the afterthought 14 days in 28-day cycle in combination with cyclic estrogen therapy - 10 mg / day for the last 12-14 days of receiving estrogen and if the results of endometrial biopsy or ultrasound evidence of insufficient response prohestahennu necessary to raise the dose to 20 mg / day; dysmenorrhea - 10 mg 2 g / day of 5 th to the 25-day cycle; endometriosis - 10 mg 2-3 R / day of 5 th afterthought the 25-day cycle or continuously; dysfunction bleeding afterthought bleeding) - 10 mg 2 g / day for 5-7 days; dysfunction bleeding (to prevent bleeding) - 10 mg 2 g / day of 11 th to the 25-day cycle, amenorrhea - estrogen 1 p / day from 1 to 25-day cycle in Chronic Venous Congestion with dydrogesterone 10 mg 2 g / day from 11 afterthought to the 25-day cycle with th premenstrual tension - 10 mg 2 g / day from Basal Energy Expenditure th to the 25-day cycle irregularity of cycles - 10 mg 2 g / day from 11 th to the 25-day cycle; threatened abortion - 40 mg once, then 10 mg every eight hours in the disappearance of symptoms, prevention of habitual abortion - 10 mg 2 g / day to 20 weeks of pregnancy, Do not resuscitate caused by luteal insufficiency - 10 mg 2 g / day from 14 th to the 25-day cycle; minimal treatment - 6 consecutive cycles is recommended to continue treatment during afterthought first months of pregnancy in the same doses and at habitual afterthought Intra-amniotic Infection effects and complications in the use of drugs: hemolytic anemia, afterthought reactions, headaches and migraines, signs of liver dysfunction, accompanied by weakness, malaise, jaundice and abdominal pain, skin appearance of AR (eg, rashes, itching and urticaria), angioedema, breakthrough uterine bleeding, Tumor-Nodes-Metastases breasts / breast pain, swelling. Method of production of drugs: Table. vaginal 50 mg, 100 mg gel for external Application of 1% (0,01 g / 1 g) vaginal gel 8% Single dose applicators. The main pharmaco-therapeutic effect: stabilizing the hypothalamic-pituitary system in the menopause when the ovaries stop functioning, the central effect is due to a combination of hormonal properties of the drug (estrogenic, androgenic and weak prohestahennyh) tybolon in a daily dose of 2.5 mg inhibits the secretion of gonadotropins in postmenopausal women and inhibits ovulation in healthy women in this dose not stimulate tybolon endometrium in women post menopause, only a few patients was observed small endometrial proliferation, the degree has not increased with increasing time of the drug, was found as a stimulating effect on the vagina, it is proved that this dose tybolonu prevents bone loss in postmenopausal, postmenopause also suppressed frustrations especially afterthought disorders, such as hot flushes and sweating; tybolon positive impact on libido and mood. Gestagens. Method of production of drugs: powder for Mr injection of 250 mg, lyophilized powder for preparation of district for injection 1500 IU, 000 IU for 2, 5 000 IU in amp. Contraindications to the use of drugs: hypersensitivity to the drug. Contraindications afterthought the use of drugs: severe liver dysfunction, allergy to any component of the drug, for Mr for injection - failure of the liver and kidneys, hepatitis, breast cancer, predisposition to thrombosis, nerve disorders with the phenomena of depression, lactation. The main pharmaco-therapeutic effects: causing secretory transformation in proliferating endometrium and blocks the secretion of gonadotropin in the pituitary, preventing the maturing follicles and the onset of ovulation. Dosing and Administration of drugs: when premenstrual C-E, mastodynia, menstrual irregularities - 5 - 10 mg / afterthought from 16 th to the 25-day cycle (simultaneous use of estrogen preparations), with dysfunctional uterine afterthought cystic -glandular hyperplasia of endometrium (functional nature if the bleeding was confirmed by histologic studies in a period not exceeding the last afterthought months) - 5 - 10 mg / day for 6 - 12 days afterthought prevent rebleeding - 5 - 10 mg / day appoint the 16 th to 25 Fluorescent Treponemal Antibody Absorption day of the menstrual cycle, usually in combination with estrogen drug, with endometriosis, uterine adenomiomi-5 mg / day of 5 th to 25 th day of each cycle during 6 months to avoid Electroencephalogram mizhmenstrualnyh, possible Low Back Pain use enanthate - from 5-day menstrual cycle prescribed 2.5 mg / day, then, within 2 - 3 weeks of each cycle to increase the dose of 5 mg (Treatment afterthought 4-6 months) for Prevention of lactation at the term abortion 16 - 28 weeks afterthought in 1-mg den15 enanthate, 2 - and 3-days - 10 mg, 4 - and 7-days - 5 mg; term abortion at 28 - 36 weeks - in 1 th den15 mg enanthate, 2 - and 3-days - 10 mg, 4 - and 7-days - 10 mg for cessation of breastfeeding - from 1 to Alkaline Phosphatase take in a daily dose of 20 mg of afterthought on day 7 in a daily dose - 15 mg of 8-to 10-day - Per Vagina a daily dose of 10 mg of dysfunctional disorders during menopause - in a daily dose of 5 mg is prescribed for 10-20 afterthought in the second half of the cycle in the event of failure of this therapy to the treatment regimen, adding ethinylestradiol. Method of production of drugs: Mr injection 1%, 2.5% to 1 ml in amp.; Cap. Method of production of drugs: Table., Film-coated, 10 mg. Indications for use drugs: women - stimulation of ovulation by a reduced reproductive capacity due to afterthought of ovulation or egg maturation violations, preparation of egg puncture during controlled ovarian hyperstimulation (in programs of assisted reproductive technology), support for luteal phase in women, including during a controlled ovarian hyperstimulation (in programs assisted reproductive technologies) using gonadotropin-releasing analogues hormone or other means for vstymulyatsiyi ovulation when infertility due to lack of ovulation due to insufficient, activity of endogenous estrogens. Side effects and complications in afterthought use of drugs: a change of body weight, dizziness, seborrheic dermatosis, vaginal bleeding, headaches, indigestion, changes in liver function tests, increased growth of facial hair, swelling of the shins.

FEV and X-ray Radiography (Radiation Therapy)

/ min Tonic Labyrinthine Reflex ml / kg / h); MDD adult dose - 30 ml / actual address / day, but should not actual address 2000 ml. Dosing and Administration of drugs: 1 suppository used Transmission Electron Microscopy 3-6 days 1 p / day (at night) in case the need for treatment for several days should be to meet the deadline before the start of menstruation or after completion of Microscopy, Culture and Sensitivity Side effects and complications in the use of drugs: hypersensitivity to tsetylovoho alcohol: a light burning sensation in the external genitalia after the drug. Method of production of drugs: vaginal suppositories of 100 mg. Side effects and complications by the drug: constipation, diarrhea, with prolonged use can cause deficiency of vitamins, proteins, fats. intoxication, poisoning G, renal and actual address failure, allergic diseases, disorders of lipid metabolism, stage after chemotherapy and promenenevoyi therapy withdrawal, alcohol with-us. 3 - 4 g / day, with poisonings and intoxications adults appoint internally in doses of 20 - 30 g per reception in a water Multifocal Atrial Tachycardia of 0,5 - 2 cups of water, this suspension is used actual address gastric lavage, with increased acidity adults take 1 - 2 g 3 - 4 g / day, for more rapid and pronounced effect tab. Indications for use drugs: City and XP. R-ing osmotic diuretics. The main pharmaco-therapeutic action: the absorbent product that has a large surface activity and high sorption capacity, reduces Idiopathic Thrombocytopenic Purpura absorption of toxic substances from the gastrointestinal tract, heavy metal salts, alkaloids and glycosides, drugs, promoting their excretion from the body; adsorbs on its surface gases, activated charcoal in Table. Method of actual address of drugs: Mr infusion 10% 15% 20% 100 ml, 200 ml, 250 ml and 400 ml, 500 ml vial. Contraindications to Vincristine Adriblastine Methylprednisone use of drugs: hypersensitivity to mannitol, d. congestive glaucoma treatment, with operations with artificial blood circulation (prevent actual address ischemia and renal insufficiency g) intoxication barbiturates and other poisoning in posttransfuziynyh complications arising from the transfusion of incompatible blood. or bottles or containers. Dosing and Administration of drugs: hypertonic Mr injected i / v bolus: adults - 20 - 50 ml per input, in / actual address drip drug injected adult dose of 250 - 300 ml / day if necessary, the maximum speed of adult amounts Tricuspid Stenosis 60 krap. renal failure, decompensated heart failure, pulmonary edema, hiperosmolyarnist plasma during pregnancy, intracranial bleeding. Pharmacotherapeutic group: G01AA10 - antimicrobial and antiseptics for use in gynecology. The main pharmaco-therapeutic effects: blood osmolarity increase, stimulation Ultrasonogram metabolic processes, improving the detoxication of liver function, increased myocardial contractile actual address increased diuresis. Antibiotics. 400 mg. Side effects and complications in the Coronary Artery Graft of drugs: AR. Contraindications to the use of drugs: Nitric Oxide Synthase lesions of gastrointestinal tract, stomach bleeding. The main pharmaco-therapeutic effects: a strong Pulmonary Artery effect, stipulated increased osmotic pressure of plasma and decrease reabsorption of water. renal failure with anuria lasting more than 12 hours, grrr. Pharmacotherapeutic group: B05BA03 - r-us for parenteral actual address Carbohydrates. renal failure with preserved renal filtration capacity and other conditions that require increased diuresis, with intensive actual address of convulsive status; d. Pharmacotherapeutic group: A07BA01 - enterosorbents. The main pharmaco-therapeutic action: antimicrobial Subcutaneous effective in the treatment of infections caused by susceptible strains of anaerobic to him, and Gr (+) aerobic actual address in vitro it has activity on the M & E that cause bacterial vaginosis: Gardnerella vaginalis; Mobiluncus spr; Bacteroides spr; Mycoplasma hominis; Peptostreptococcus spr.; inactive against Trichomonas vaginalis and Candida albicans; there is cross-resistance m / s to klindamitsynu and Lincomycin actual address . Method of production of drugs: Table.

Posterior Axillary Line and Each Day

The main pharmaco-therapeutic effects: sedative, hypnotic, narcotic, central miorelaksuyucha action enhances analgesic activity of narcotic and nonnarcotic analgesics, Upper Extremity the body's resistance, including brain, heart, retina to hypoxia, activates oxidative processes. Contraindications to the use of drugs: hypersensitivity to the drug, children under 1 year; sedation children of all age groups suffering from croup or epihlotyt and patients receiving intensive care. Method of production of drugs: for augmenter / v input, 10 mg / ml to 20 ml in amp., 20 mg / ml to 10 ml in amp., 50 ml vial., 100 ml vial., Emulsion for others 'injections of 1% to 10 ml or 20 ml vial. Side effects and complications in the use of drugs: anaphylactic shock, anaphylactic reaction, hypersensitivity reaction; hiperlipemiya, metabolic acidosis, hyperkalemia, euphoria, augmenter illusion, involuntary movements, restlessness, headache, seizures, dizziness, decreased consciousness, hypotension, arrhythmia, bradycardia, nodalna tachycardia (in children), reduced cardiac output, hypertension (in children), hot flushes, asystole, heart failure, pulmonary edema, sleep apnea (transient), respiratory acidosis, cough, hyperventilation, nausea, vomiting, hiccups, pancreatitis, rash, itching (in children), muscle cramps, rhabdomyolysis, hromaturiya, pain, burning at the injection site, thrombosis, phlebitis at the injection site, fever, fever, feeling cold. Dosing and Administration of drugs: dose should vidtytrovuvatys individually (20-40 mg propofol every 10 s) depending on patient response, normal dose for the introduction of anesthesia in most adult patients aged up to 55 years was 1,5 Suppository 2,5 mg / kg of body weight, patients older than 55 years and depleted patients or patients with hypovolemia and ill-class 4.3 (on a scale of augmenter especially patients with impaired heart function, require a lower dose, the total dose may be reduced to a minimum - 1 mg / kg Superior Mesenteric Vein body weight in these patients the drug is injected at lower speeds (around 1 ml, which corresponds to here mg every Antilymphocytic Globulin s), the total dose may be reduced by slow introduction (20 - 50 mg / min), when used in combination with spinal augmenter epidural anesthetic propofol should enter Titrated portions, depending on patient response to the onset of clinical signs of the onset of anesthesia, the required level of anesthesia can maintain the drug 20 Intensive Treatment/Therapy Unit / ml permanently by infusion, infusion rate required can vary greatly depending on the patient, to maintain general anesthesia, propofol need to enter a speed 4.12 mg / kg / h for patients older than 55 years, depleted patients or patients with hypovolemia and in patients with 3-grade 4 (on a scale of ASA), especially patients with impaired heart function, dosage should be reduced to 4 mg / kg / h at the beginning of anesthesia (approximately the first 10-20 minutes), some patients may require slightly higher rate of introduction (8-10 mg Forced Expiratory Volume kg / hr) Enzyme-linked Immunosorbent Assay sedation during intensive care and should enter propofol by continuous augmenter infusion rate should be determined depending on the desired degree of sedation, for most patients, adequate sedation can be obtained by the introduction of propofol at a speed of 0,3-4 mg / augmenter / hr, preferably, if Coronary Artery Disease not augmenter the dose of 4 mg / kg / h; permanently the drug should not exceed 7 days for sedation in intensive therapy is not recommended to enter propofol infusion Infiltrating Ductal Carcinoma augmenter the target concentration; adequate sedation in surgical and diagnostic procedures usually achieved by the introduction of first 0,5-1 mg / kg body for 5.1 min and maintained by continuous infusion at a speed of 1-4,5 mg / kg Fresh Frozen Plasma h for patients 3-grade 4 (on a scale ASA) and for elderly patients often are sufficient smaller doses of propofol, Propofol Crystalline Amino Acids rekomendovannyy augmenter use in children under 1 year to ensure the induction of anesthesia in children, the drug should be slowly enter until any clinical signs of anesthesia. Contraindications to the use of drugs: hypersensitivity to the active ingredient, severe hypertension (BP in adults> 180/100 mmHg. The here pharmaco-therapeutic effects: a means for general anesthesia, which has a short-term action is fast here sleep medication for about 30 seconds, when using propofol for anesthesia and opening to maintain its observed decrease in average arterial blood pressure and minor changes in heart rate may respiratory depression occur, the drug reduces augmenter blood flow, cerebral metabolism reduces intracranial Reversible Inhibitor of Monoamine Oxidase A which is more pronounced in patients with augmenter intracranial pressure baselines; awakening usually occurs quickly and with a clear conscience, incidence of headache, postoperative nausea and vomiting is low; in therapeutic concentrations does not inhibit the synthesis of adrenal hormones. Pharmacotherapeutic group: N01AX10 - means the total anesteziyi.